Shan Zeng

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Venues

Cancer communications (London, England)

BMJ open

Journal of cellular biochemistry

Journal of cellular and molecular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yijia Tang, Guangzu Cui, Haicong Liu, Ying Han, Changjing Cai, Ziyang Feng, Hong Shen, Shan Zeng
Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer communications (London, England) 44 (6) (2024)
Yijia Tang, Guangzu Cui, Haicong Liu, Ying Han, Changjing Cai, Ziyang Feng, Hong Shen, Shan Zeng
Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer communications (London, England) 44 (6) (2024)
Yijia Tang, Guangzu Cui, Haicong Liu, Ying Han, Changjing Cai, Ziyang Feng, Hong Shen, Shan Zeng
Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer communications (London, England) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Yijia Tang, Guangzu Cui, Haicong Liu, Ying Han, Changjing Cai, Ziyang Feng, Hong Shen, Shan Zeng
Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer communications (London, England) (2024)
Taili Chen, Yan Zhang, Jiayi Liu, Zhenzhen Rao, Mian Wang, Hong Shen, Shan Zeng
Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ open 13 (12) (2023)
Taili Chen, Yan Zhang, Jiayi Liu, Zhenzhen Rao, Mian Wang, Hong Shen, Shan Zeng
Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ open 13 (12) (2023)
Taili Chen, Yan Zhang, Jiayi Liu, Zhenzhen Rao, Mian Wang, Hong Shen, Shan Zeng
Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ open 13 (12) (2023)
Taili Chen, Yan Zhang, Jiayi Liu, Zhenzhen Rao, Mian Wang, Hong Shen, Shan Zeng
Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ open 13 (12) (2023)
Min He, Ying Han, Changjing Cai, Ping Liu, Yihong Chen, Hong Shen, Xingyuan Xu, Shan Zeng
CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma. Journal of cellular and molecular medicine 25 (7) (2021)
Ying Han, Yinghui Peng, Yaojie Fu, Changjing Cai, Cao Guo, Shanshan Liu, Yiyi Li, Yihong Chen, Edward Shen, Kexin Long, Xinwen Wang, Jian Yu, Hong Shen, Shan Zeng
MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her-2/PI3K/AKT Signaling. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 7 (13) (2020)
Ganlu Deng, Yihong Chen, Cao Guo, Ling Yin, Ying Han, Yiyi Li, Yaojie Fu, Changjing Cai, Hong Shen, Shan Zeng
BMP4 promotes the metastasis of gastric cancer by inducing epithelial-mesenchymal transition via ID1. Journal of cell science 133 (11) (2020)
Hong Shen, Ling Yin, Ganlu Deng, Cao Guo, Ying Han, Yiyi Li, Changjing Cai, Yaojie Fu, Shanshan Liu, Shan Zeng
Knockdown of Beclin-1 impairs epithelial-mesenchymal transition of colon cancer cells. Journal of cellular biochemistry 119 (8) (2018)

Shan Zeng.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shan Zeng